文献速递免疫规划卫生政策与健康促进慢病防控与筛查

美国50-64岁弱势少数族裔与一般人群成人肺炎球菌疫苗接种策略的成本效果比较

Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population.
PubMed 文献 · Vaccine · 2019-03-04

研究用马尔可夫队列模型评估美国50岁弱势少数族裔(以黑人数据代理)与一般人群的肺炎球菌疫苗接种策略成本效果。结果显示,为所有50岁人群接种两种疫苗预防疾病最多,但每获得一个QALY成本超过25万美元;当前CDC建议在经济上有利,若多糖疫苗对非菌血症性肺炎有效或 uptake 增加,为所有50岁人群接种多糖疫苗成本低于10万美元/QALY,在黑人队列中更明显。

要点

  • 当前CDC建议在弱势少数族裔和一般人群中均经济有利。
  • 为所有50岁人群接种两种疫苗成本超过25万美元/QALY。
  • 多糖疫苗对非菌血症性肺炎有效时,全员接种成本低于10万美元/QALY。

核心结论

  • 尽管肺炎球菌流行病学变化,当前CDC建议在弱势少数族裔和一般人群队列中均受支持。
  • 在某些疫苗 uptake 和有效性假设下,可考虑为所有50岁人群接种多糖疫苗,尤其以缩小 racial 健康差异为优先时。

研究设计与样本

  • 马尔可夫队列模型,评估美国50岁弱势少数族裔(以黑人数据代理)和一般人群队列的肺炎球菌疫苗接种策略成本效果。
  • 策略包括基于年龄或慢性病标准接种一种或两种可用肺炎球菌疫苗,采用美国医疗保健视角,年贴现率3%。
  • 数据来自美国数据库和医学文献,校准肺炎球菌疾病发病率、疫苗血清型分布、年龄和种族特异性慢性病分布及成本。

主要发现

  • 在黑人 and 一般人群50岁队列中,为所有50岁人群接种两种疫苗预防疾病最多,但每获得QALY成本超过25万美元。
  • 当假设多糖疫苗对非菌血症性肺炎无效时,当前CDC建议(免疫缺陷者接种两种疫苗,其他高危条件接种多糖疫苗)在两种人群中均经济有利。
  • 若多糖疫苗对非菌血症性肺炎有效或更简单的年龄基础建议增加疫苗 uptake,为所有50岁人群接种多糖疫苗成本低于10万美元/QALY,在黑人队列中更明显。

关键数值与推荐

  • 当前CDC建议:免疫缺陷者接种两种疫苗,其他高危条件接种多糖疫苗。
  • 为所有50岁人群接种两种疫苗成本超过25万美元/QALY。
  • 多糖疫苗对非菌血症性肺炎有效或 uptake 增加时,为所有50岁人群接种多糖疫苗成本低于10万美元/QALY。

临床怎么用

  • 在弱势少数族裔和一般人群中,遵循当前CDC建议进行肺炎球菌疫苗接种具有经济性。
  • 若多糖疫苗对非菌血症性肺炎有效或能提高接种率,可考虑为所有50岁人群接种多糖疫苗,尤其以缩小健康差异为目标时。

局限性

  • 使用黑人数据作为弱势少数族裔的代理。
  • 结果基于模型假设和疫苗有效性假设,需结合实际接种情况解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Changing pneumococcal disease epidemiology due to childhood vaccination has prompted re-examination of US adult pneumococcal vaccination policies, as have considerations of greater pneumococcal disease incidence and higher prevalence of conditions that increase risk in underserved minority populations. Prior analyses suggest routine pneumococcal vaccination at age 50 could be considered, which could disproportionately benefit underserved populations. METHODS: A Markov cohort model estimated the cost-effectiveness of US pneumococcal vaccination policies in hypothetical 50-year-old underserved minority and general population cohorts. Strategies included receiving one or both available pneumococcal vaccines based on age- or chronic condition-specific criteria. US databases and medical literature data calibrated pneumococcal illness incidence, vaccine serotype distributions, age- and race-specific chronic condition distributions, and costs. Black population data were used as a proxy for underserved minorities. We took a US healthcare perspective, discounting at 3%/year. One-way and probabilistic sensitivity analyses were performed and scenarios modeling differing vaccine assumptions were examined. RESULTS: In both black and general population 50-year-olds, giving both pneumococcal vaccines to all 50-year-olds prevented the most disease, but cost >$250,000 per quality adjusted life year (QALY) gained. Current CDC recommendations (both vaccines for the immunocompromised, polysaccharide vaccine for other high-risk conditions) were economically favorable in either population when analyses assumed polysaccharide vaccine was ineffective against nonbacteremic pneumococcal pneumonia (NBP). If polysaccharide vaccine is effective against NBP or if less complex age-based vaccination recommendations result in increased vaccine uptake, giving polysaccharide vaccine to all 50-year-olds cost <$100,000/QALY; this effect was more pronounced in black cohorts. Results were robust in 1-way and probabilistic sensitivity analyses. CONCLUSIONS: Despite changes in pneumococcal epidemiology, current CDC recommendations were favored in underserved minority and general population cohorts. Polysaccharide vaccine for all 50-year-olds could be considered under some vaccine uptake and effectiveness assumptions, particularly if mitigating racial health disparities in pneumococcal disease is a priority.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wateska AR, Nowalk MP, Lin CJ, et al. Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general population. Vaccine. 2019. PMID: 30846259. doi:10.1016/j.vaccine.2019.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。